The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high‐dose cisplatin Academic Article Article uri icon

Overview

MeSH Major

  • Amyotrophic Lateral Sclerosis
  • Biomarkers
  • Muscle Weakness
  • Nerve Growth Factors
  • Neuropeptides

abstract

  • Vomiting was prevented in two thirds of patients treated with MDL plus ondansetron, a result similar to that observed in earlier trials of MDL alone. The lack of improvement in emetic control by the addition of ondansetron suggests that vomiting mediated through 5-HT3 receptors is already effectively blocked. Emesis that occurs despite pretreatment with MDL is likely mediated by other mechanisms.

publication date

  • January 1994

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19940201)73:3<720::AID-CNCR2820730336>3.0.CO;2-3

PubMed ID

  • 8299095

Additional Document Info

start page

  • 720

end page

  • 3

volume

  • 73

number

  • 3